Appeal 2006-2945
Application 10/041,958
INTRODUCTION
The claims are directed to a dosage formulation. Claims 26, 28, 30,
31, and 32 are illustrative:
26. A dosage formulation comprising an effective amount of human
or humanized monoclonal antibodies, the antibodies consisting of antibodies
neutralizing Shiga like toxin II in vivo, wherein the antibodies are
specifically reactive with a single subunit of the Shiga like toxin II produced
by Escherichia coli which causes hemolytic uremic syndrome, to prevent or
treat hemolytic uremic syndrome in a human.
28. The dosage formulation of claim 26, wherein the antibodies are
produced by recombinant DNA methodology.
30. The dosage formulation of claim 26, wherein the antibodies bind
to the alpha subunit of the Shiga like toxin II.
31. The dosage formulation of claim 26 wherein the antibodies are
effective to prevent neurological signs of hemolytic uremic syndrome or
lesions, wherein the neurological signs or lesions are selected from the group
consisting of bloody diarrhea, acute renal failure, cerebral hemorrhaging,
bacterial shedding into feces, bacterial lesions, paddling, head-pressing,
ataxia, convulsions and wasting.
32. The dosage formulation of claim 26, wherein the antibodies are
effective to prolong survival.
The Examiner relies on the following prior art references to show
unpatentability:
Queen WO 90/07861 Jul. 26, 1990
Krivan US 5,512,282 Apr. 30, 1996
Williams US 6,080,400 Jun. 27, 2000
2
Page: Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 Next
Last modified: September 9, 2013